Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHSFT/BTOG Steering Committee, UK, talks on a real-world investigation into whether patients with non-small cell lung cancer (NSCLC) more than 50% PD-L1 positive should have pembrolizumab monotherapy or pembrolizumab plus chemotherapy, specifically in never-smokers. The multivariate analysis data of the Phase III trials KEYNOTE-024 (NCT02142738) trial and KEYNOTE-042 (NCT02220894) had suggested poorer survival outcomes for patients with NSCLC who are never-smokers receiving pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy, which was further demonstrated by a real-world analysis. This interview took place at the BTOG 2022 Summer Meeting congress in London.
